Suppr超能文献

具有双重激动肽的胰高血糖素受体的冷冻电子显微镜结构。

Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.

机构信息

School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, China.

Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.

出版信息

J Biol Chem. 2020 Jul 10;295(28):9313-9325. doi: 10.1074/jbc.RA120.013793. Epub 2020 May 5.

Abstract

Unimolecular dual agonists of the glucagon (GCG) receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) are a new class of drugs that are potentially superior to GLP-1R-specific agonists for the management of metabolic disease. The dual-agonist, peptide 15 (P15), is a glutamic acid 16 analog of GCG with GLP-1 peptide substitutions between amino acids 17 and 24 that has potency equivalent to those of the cognate peptide agonists at the GCGR and GLP-1R. Here, we have used cryo-EM to solve the structure of an active P15-GCGR-G complex and compared this structure to our recently published structure of the GCGR-G complex bound to GCG. This comparison revealed that P15 has a reduced interaction with the first extracellular loop (ECL1) and the top of transmembrane segment 1 (TM1) such that there is increased mobility of the GCGR extracellular domain and at the C terminus of the peptide compared with the GCG-bound receptor. We also observed a distinct conformation of ECL3 and could infer increased mobility of the far N-terminal His-1 residue in the P15-bound structure. These regions of conformational variance in the two peptide-bound GCGR structures were also regions that were distinct between GCGR structures and previously published peptide-bound structures of the GLP-1R, suggesting that greater conformational dynamics may contribute to the increased efficacy of P15 in activation of the GLP-1R compared with GCG. The variable domains in this receptor have previously been implicated in biased agonism at the GLP-1R and could result in altered signaling of P15 at the GCGR compared with GCG.

摘要

胰高血糖素 (GCG) 受体 (GCGR) 和胰高血糖素样肽-1 受体 (GLP-1R) 的单分子双重激动剂是一类新的药物,它们在代谢疾病的治疗方面可能优于 GLP-1R 特异性激动剂。双重激动剂肽 15 (P15) 是 GCG 的谷氨酸 16 类似物,GLP-1 肽在氨基酸 17 和 24 之间发生取代,其效力与 GCGR 和 GLP-1R 上的同源肽激动剂相当。在这里,我们使用 cryo-EM 解决了活性 P15-GCGR-G 复合物的结构,并将该结构与我们最近发表的 GCGR-G 复合物与 GCG 结合的结构进行了比较。这种比较表明,P15 与第一个细胞外环 (ECL1) 和跨膜片段 1 (TM1) 的顶部的相互作用减少,使得 GCGR 细胞外结构域和肽的 C 末端的运动性增加,与 GCG 结合的受体相比。我们还观察到 ECL3 的独特构象,并可以推断出 P15 结合结构中肽的 N 端 His-1 残基的运动性增加。这两种肽结合的 GCGR 结构中这些构象变化的区域也与 GCGR 结构和先前发表的 GLP-1R 肽结合结构之间存在差异,这表明更大的构象动力学可能有助于 P15 与 GCG 相比在激活 GLP-1R 方面的功效提高。该受体的可变结构域先前与 GLP-1R 的偏向激动作用有关,并且可能导致 P15 在 GCGR 上与 GCG 相比信号转导发生改变。

相似文献

2
Structural analysis of the dual agonism at GLP-1R and GCGR.GLP-1R 和 GCGR 的双重激动剂的结构分析。
Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2303696120. doi: 10.1073/pnas.2303696120. Epub 2023 Aug 7.

引用本文的文献

3
7
Structural analysis of the dual agonism at GLP-1R and GCGR.GLP-1R 和 GCGR 的双重激动剂的结构分析。
Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2303696120. doi: 10.1073/pnas.2303696120. Epub 2023 Aug 7.

本文引用的文献

2
The Molecular Control of Calcitonin Receptor Signaling.降钙素受体信号传导的分子调控
ACS Pharmacol Transl Sci. 2019 Jan 11;2(1):31-51. doi: 10.1021/acsptsci.8b00056. eCollection 2019 Feb 8.
3
Rules of Engagement: GPCRs and G Proteins.作用机制:G蛋白偶联受体与G蛋白
ACS Pharmacol Transl Sci. 2018 Sep 7;1(2):73-83. doi: 10.1021/acsptsci.8b00026. eCollection 2018 Nov 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验